Quick Answer
Summit Therapeutics Inc. reported Net Income Loss of -$1.08 billion for the year ending 2025.
- Summit Therapeutics Inc. showed a decrease of -387.8% in Net Income Loss from 2024 to 2025.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$6.38 million | Q1 2020: -$6.13 million | Q2 2020: -$15.28 million | Q3 2020: -$17.74 million | Q1 2021: -$17.49 million | Q2 2021: -$24.42 million | Q3 2021: -$19.60 million | Q1 2022: -$21.40 million | Q2 2022: -$16.77 million | Q3 2022: -$21.39 million | Q1 2023: -$542.38 million | Q2 2023: -$14.72 million | Q3 2023: -$21.27 million | Q1 2024: -$43.47 million | Q2 2024: -$60.39 million | Q3 2024: -$56.25 million | Q1 2025: -$62.91 million | Q2 2025: -$565.71 million | Q3 2025: -$231.79 million.
- Over the full 8 years of available data (2019 to 2025), Summit Therapeutics Inc.'s Net Income Loss has declined by 10,032.7%.
- Historical annual values: Fiscal year 2025: -$1.08 billion | Fiscal year 2024: -$221.32 million | Fiscal year 2023: -$614.93 million | Fiscal year 2022: -$78.78 million | Fiscal year 2021: -$88.60 million | Fiscal year 2020: -$52.70 million | Fiscal year 2019: -$29.13 million | Fiscal year 2019: $10.87 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: